Provided by Tiger Fintech (Singapore) Pte. Ltd.

Mesoblast

10.72
+0.41003.98%
Post-market: 10.800.0800+0.75%18:36 EDT
Volume:155.76K
Turnover:1.66M
Market Cap:1.36B
PE:-11.62
High:10.89
Open:10.55
Low:10.46
Close:10.31
Loading ...

Mesoblast Expands Payer Coverage for Ryoncil

MT Newswires Live
·
17 Apr

Mesoblast Expands Insurance Coverage for Ryoncil to 104 Million Lives in US

MT Newswires Live
·
17 Apr

Mesoblast Expands Ryoncil Coverage to Over 100 Million US Lives

TIPRANKS
·
17 Apr

Mesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US Lives

GlobeNewswire
·
17 Apr

Mesoblast Limited Announces Cessation of Securities

TIPRANKS
·
14 Apr

Mesoblast Limited Issues Over 8 Million New Securities

TIPRANKS
·
14 Apr

Mesoblast Limited Announces Quotation of New Securities

TIPRANKS
·
14 Apr

Mesoblast Limited Issues New Equity Securities Under Employee Incentive Scheme

TIPRANKS
·
14 Apr

Mesoblast Limited Issues New Equity Securities for Employee Incentive

TIPRANKS
·
08 Apr

Top broker says Mesoblast shares can rocket 100%

MotleyFool
·
08 Apr

Mesoblast Considers Ryoncil, Revascor to Be US-Origin Products

MT Newswires Live
·
04 Apr

HotCopper Highlights for Week 14 – Mesoblast, Cettire, Neurizon & more!

The Market Herald
·
04 Apr

Friday’s HotCopper Trends: Mesoblast dodges tariffs, Orthocell’s FDA tick | April 4, 2025

The Market Herald
·
04 Apr

BRIEF-Mesoblast Says Mesoblast Cell Therapy Products Not Subject To U.S. Tariffs

Reuters
·
04 Apr

Mesoblast Says Products Exempt From US Tariffs

MT Newswires Live
·
04 Apr

BRIEF-Mesoblast Says Allogeneic Cell Therapy Products Are Designated ‘U.S. Country Of Origin’ And Not Subject To U.S. Tariffs

Reuters
·
04 Apr

Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin’ and Not Subject to U.S. Tariffs

THOMSON REUTERS
·
04 Apr

Mesoblast Ltd - Cell Therapy Products Not Subject to U.S. Tariffs

THOMSON REUTERS
·
04 Apr

Mesoblast - Allogeneic Cellular Products, Including Ryoncil and Revascor, Will Not Be Subject to Tariffs

THOMSON REUTERS
·
04 Apr

Mesoblast Files Meeting Request With FDA for Ischemic Heart Failure Treatment Candidate

MT Newswires Live
·
03 Apr